Skip to main content

Here's why Cytokinetics stock tumbled 42% Thursday

The company has hoped that omecamtiv mecarbil for chronic heart failure patients would be its first drug in the nearly quarter century since it was founded.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.